Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies

Oncology Letters

Volumn 2, Issue 6, 2011, Pages 1131-1137

  Vranic, Semir ^a,b   Gatalica, Zoran ^a   Wang, Zhao Yi ^a,c  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen receptor; Apocrine breast carcinoma; Apocrine cell line; MDA MB 453

Indexed keywords

ANDROGEN RECEPTOR; CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTROGEN RECEPTOR ALPHA; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROGESTERONE RECEPTOR; PROTEIN P16; RETINOBLASTOMA PROTEIN;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL PROLIFERATION; CHROMOSOME 17; CHROMOSOME 7; CHROMOSOME ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE LOCUS; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MOLECULAR CLONING; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 80052723989     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.375     Document Type: Article

References (48)

1. Tavassoli FA and Devilee P (eds.): World Health Organization Classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. IARC Press: Lyon 2003.
2. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
3. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001.
4. Weigelt B, Horlings HM, Kreike B, et al: Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 216: 141-150, 2008.
5. Gatalica Z: Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol Res Pract 193: 753-758, 1997.
6. Tavassoli FA, Purcell CA, Bratthauer GL, et al: Androgen receptor expression along with loss of bcl-2, ER, and PR expression in benign and malignant apocrine lesions of the breast: implications for therapy. Breast J 2: 261-269, 1996.
7. Bratthauer GL, Lininger RA, Man YH and Tavassoli FA: Androgen and estrogen receptor mRNA status in apocrine carcinomas. Diagn Mol Pathol 11: 113-118, 2002.
8. Farmer P, Bonnefoi H, Becette V, et al: Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24: 4660-4671, 2005.
9. Burdall SE, Hanby AM, Lansdown MRJ and Speirs V: Breast cancer cell lines: friend or foe? Breast Cancer Res 5: 89-95, 2003.
10. Lacroix M and Leclercq G: Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83: 249-289, 2004.
11. Kao J, Salari K, Bocanegra M, et al: Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 4: e6146, 2009.
12. Neve RM, Chin K, Fridlyand J, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-27, 2006.
13. Naderi A and Hughes-Davies L: A functionally significant cross-talk between androgen receptor and erbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 10: 542-548, 2008.
14. Chia KM, Liu J, Francis GD and Naderi A: A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasma 13: 154-66, 2011.
15. De Longueville F, Lacroix M, Barbuto AM, et al: Molecular characterization of breast cancer cell lines by a low-density microarray. Int J Oncol 27: 881-892, 2005.
16. Doane AS, Danso M, Lal P, et al: An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25: 3994-4008, 2006.
17. Hall RE, Birrell SN, Tilley WD and Sutherland RL: MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression. Eur J Cancer 30A: 484-490, 1994.
18. Vranic S, Tawfik O, Palazzo J, et al: EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol 23: 644-653, 2010.
19. Bhargava R, Beriwal S, Striebel JM and Dabbs DJ: Breast cancer molecular class ERBB 2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR. Appl Immunohistochem Mol Morphol 18: 113-118, 2010.
20. Varga Z, Zhao J, Ohlschlegel C, Odermatt B and Heitz PU: Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer. Histopathology 44: 332-338, 2004.
21. Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z and Wang ZY: A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene 30: 770-780, 2011.
22. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y and Deuel TF: A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen-and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA 103: 9063-9068, 2006.
23. Subhawong AP, Subhawong T, Nassar H, et al: Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol 33: 163-75, 2009.
24. Milde-Langosch K, Bamberger AM, Rieck G, Kelp B and Löning T: Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat 67: 61-70, 2001.
25. Elayat G, Selim AG and Wells CA: Alterations of the cell cycle regulators cyclin D1, cyclin A, p27, p21, p16, and pRb in apocrine metaplasia of the breast. Breast J 15: 475-482, 2009.
26. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145, 2007.
27. Shaffer LG and Tommerup N (eds.): ISCN 2005. An International System for Human Cytogenetic Nomenclature. Karger, Basel, 2005.
28. Vranic S, Teruya B, Repertinger S, Ulmer P, Hagenkord J and Gatalica Z: Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer 117: 48-53, 2011.
29. Shackelford W, Deng S, Murayama K and Wang J: A new technology for mutation detection. Ann N Y Acad Sci 1022: 257-262, 2004.
30. Hollestelle A, Nagel JH, Smid M, et al: Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat 121: 53-64, 2010.
31. Arriola E, Marchio C, Tan DS, et al: Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 88: 491-503, 2008.
32. Mackay A, Tamber N, Fenwick K, et al: A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast Cancer Res Treat 118: 481-498, 2009.
33. Taniyama K, Ishida K, Toda T, et al: Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas. Breast Cancer 15: 231-240, 2008.
34. Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA and Parsons SJ: Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 20: 1465-1475, 2001.
35. Hollestelle A, Elstrodt F, Nagel JHA, Kallemeijn WW and Schutte M: Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Ther 5: 195-201, 2007.
36. Von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE and Boss GR: Ras activation in human breast cancer. Breast Cancer Res Treat 62: 51-62, 2000.
37. Torii S, Yamamoto T, Tsuchiya Y and Nishida E: ERK MAP kinase in G1 cell cycle progression and cancer. Cancer Sci 97: 697-702, 2006.
38. Lu Z and Xu S: ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life 58: 621-631, 2006.
39. Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007.
40. McCubrey JA, Steelman LS, Chappell WH, et al: Role of the RAF/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophysic Acta 1773: 1263-1284, 2007.
41. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
42. Capela G, Cronauer-Mitra S, Peinado MA and Perucho M: Frequency and spectrum of mutations at codons 12 and 13 of the C-K-Ras gene in human tumors. Environ Health Perspect 93: 125-131, 1991.
43. Myakis S, Sourvinos G and Spandidos DA: Differential expression and mutation of the ras family genes in human breast cancer. Biochem Biophys Res Commun 251: 609-612, 1998.
44. Sánchez-Muñoz A, Gallego E, de Luque V, et al: Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer 10: 136, 2010.
45. Karnoub AE and Weinberg RA: Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9: 517-531, 2008.
46. Geradts J and Wilson PA: High frequency of aberrant p16(INK4A) expression in human breast cancer. Am J Pathol 149: 15-20, 1996.
47. Emig R, Magener A, Ehemann V, et al: Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. Br J Cancer 78: 1661-1668, 1998.
48. Di Vinci A, Perdelli L, Banelli B, et al: p16INK4a promoter methylation and protein expression in breast fibroadenoma and carcinoma. Int J Cancer 114: 414-421, 2005.